Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Income Before Tax
Profit after all operating and non-operating items but before income tax.
Vir Biotechnology, Inc.NASDAQ: VIR
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$125.53M, compared with -$120.95M a year earlier. Trailing-twelve-month income before tax was -$442.35M.
Context
- Income before tax amounted to 638.6% of revenue in FY2025, down 66.4 pp from a year earlier.
- Income before tax increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -$125.53M or moves back toward the trailing-twelve-month quarterly average of -$110.59M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (437.77M) USD
- Year-over-year change
- +16.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (437.77M) | +16.3% |
| FY2024 | 2024-12-31 | (523.11M) | +16.7% |
| FY2023 | 2023-12-31 | (628.19M) | -183.3% |
| FY2022 | 2022-12-31 | 754.28M | +37.2% |
| FY2021 | 2021-12-31 | 549.8M | — |
Income Before Tax vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.6% is the 4th highest of 10, against a peer median of -26.9%.
- Income before tax amounts to 675.4% of revenue for VIR, versus a peer median of 72.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $160.72M USD | +309.9% | — | 84.0% | |
| LTM Mar 2026 | -$6.38M USD | +83.8% | — | 9.0% | |
| LTM Mar 2026 | -$61.89M USD | +37.4% | — | 89.4% | |
| LTM Mar 2026 | -$86.19M USD | -117.6% | — | 14.5% | |
| LTM Mar 2026 | -€137.61M EUR | -76.1% | — | 88.0% | |
| LTM Mar 2026 | -$175.83M USD | -26.9% | — | — | |
| LTM Jun 2026 | -$381.19M USD | -1084.0% | — | 40.5% | |
| LTM Mar 2026 | -$442.35M USD | +23.6% | — | 675.4% | |
| LTM Jun 2026 | -€1.64B EUR | -321.6% | — | 61.9% | |
| LTM Sep 2026 | -$2.73B USD | +13.4% | — | 108.1% | |
| Peer median (excluding VIR) | — | -26.9% | — | 72.9% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.62B | 86.18M | 74.21M | 68.56M |
| Cost of Revenue | 513.87M | 620.97M | 572.83M | 478.65M | 11.71M |
| Gross Profit | 581.54M | 994.83M | (486.65M) | (404.44M) | 56.85M |
| Gross Margin | 53.1% | 61.6% | -564.7% | -545.0% | 82.9% |
| Research & Development | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 92.07M |
| Operating Expenses | 160.79M | 161.76M | 197.66M | 182.73M | 524.87M |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBITDA | 555.61M | 761.06M | (641.64M) | (508.91M) | (426.09M) |
| EBITDA Margin | 50.7% | 47.1% | -744.5% | -685.8% | -621.5% |
| Operating Income | 420.75M | 833.07M | (684.31M) | (587.17M) | (468.02M) |
| Operating Margin | 38.4% | 51.6% | -794.0% | -791.3% | -682.7% |
| Interest Income | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 129.05M | (78.79M) | 56.11M | 64.06M | 30.25M |
| Income Before Tax | 549.8M | 754.28M | (628.19M) | (523.11M) | (437.77M) |
| Pre-Tax Margin | 50.2% | 46.7% | -728.9% | -704.9% | -638.6% |
| Income Tax Expense | 21.22M | 238.44M | (13.08M) | (1.15M) | 217K |
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Net Margin | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (Basic) | 4.07 | 3.89 | (4.59) | (3.83) | (3.16) |
| EPS (Diluted) | 3.96 | 3.83 | (4.59) | (3.83) | (3.16) |
| Weighted Avg Shares | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M |
| Weighted Avg Shares (Diluted) | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.